Vanda Pharmaceuticals Inc. (VNDA) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018

Full year 2020 total revenues expected to be between $240 million and $260 million

Results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis reported today

Total revenues were $60.9 million in the fourth quarter of 2019, a 15% increase compared to $53.0 million in the fourth quarter of 2018. Total revenues were $227.2 million for the full year 2019, an 18% increase compared $193.1 million for the full year 2018.

HETLIOZ^® net product sales were $38.6 million in the fourth quarter of 2019, a 19% increase compared to $32.4 million in the fourth quarter of 2018. HETLIOZ^® net product sales were $143.0 million for the full year 2019, a 23% increase compared to $115.8 million for the full year 2018.

Fanapt^® net product sales were $22.3 million in the fourth quarter of 2019, an 8% increase compared to $20.6 million in the fourth quarter of 2018. Fanapt^® net product sales were $84.2 million for the full year 2019, a 9% increase compared to $77.3 million for the full year 2018.

Cash, cash equivalents and marketable securities (Cash) were $312.1 million as of December 31, 2019, representing an increase to Cash of $54.8 million compared to December 31, 2018.

Results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis were reported today. Vanda will reassess EPIONE 2 and determine next steps.

Enrollment in the Phase III study of tradipitant in gastroparesis (VP-VLY-686-3301) is ongoing.

Vanda expects to complete the Phase III program of tradipitant in motion sickness and file a New Drug Application with the U.S. Food and Drug Administration (FDA) in 2020.

Vanda continues to engage with the FDA over the requirement of a 9-month dog toxicity study.